AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
U.S. President Donald Trump said the U.S. was talking to the right people in Iran to make a deal on Tuesday (24 March), as Pakistan's Prime Min...
Pakistan offered to host talks between Iran and the U.S. to bring about an end...
Voting has ended in Denmark’s parliamentary election, with Prime Minister Mette Frederiksen seeking a third term after a campaign shaped by t...
Türkiye is pursuing a cautious approach to the escalating Middle East conflict while maintaining regional ties, President Recep Tayyip Erdoğa...
Traders placed more than $500 million in oil bets minutes before Donald Trump announced a delay to planned strikes on Iran, ...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
The pilot and co-pilot of an Air Canada Express regional jet were killed after it collided with a fire truck while landing at New York's LaGuardia airport late on Sunday, in an incident that closed the airport, authorities and U.S. media said.
U.S. President Donald Trump said the U.S. was talking to the right people in Iran to make a deal on Tuesday (24 March), as Pakistan's Prime Minister offered to host peace talks between the two countries to bring about an end to the conflict.
Trump says U.S. found “major points of agreement” with Iran and has paused strikes on Iranian power plants, but Tehran denies any direct talks or negotiations, contradicting U.S. claims - latest on Middle East conflict.
Violent clashes broke out between police and opposition protesters in Tirana on Sunday (22 March) as demonstrators were demanding the resignation of the Albanian government following corruption allegations against the deputy prime minister.
FinaFinal results from Slovenia’s parliamentary elections indicate a near tie between the Slovenian Democratic Party (SDS) and the liberal Freedom Movement Slovenia (GS), leaving neither side with a clear path to power.
The UK Health Security Agency (UKHSA) said that as of Wednesday evening, it has identified six new cases of meningococcal disease in Kent, bringing the total of confirmed or suspected cases to at least 27.
The Scottish Parliament has voted against legalising assisted dying, ending a years-long campaign to make Scotland the first part of the UK to allow the practice.
The war in the Middle East is beginning to disrupt the flow of critical medicines to Gulf countries, raising concerns about the supply of cancer treatments and other temperature-sensitive drugs, according to pharmaceutical industry executives.
The World Health Organization (WHO) has released $2m in emergency funding to support health responses in Lebanon, Iraq and Syria as escalating regional conflict strains hospitals, raises displacement and increases pressure on already fragile health systems.
Measles cases across Europe and Central Asia fell sharply in 2025 compared to the previous year but health officials have warned that the risk of fresh outbreaks remains unless vaccination gaps are urgently addressed.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment